Genomic Medicine and Individual Autonomy: Reflections on Knowledge Societies and Governmentality

Abstract

Highlights: Public health relevance—How does this work relate to a public health issue? Examines how genomic medicine and regulatory frameworks reshape disease classification, healthcare access, and surveillance with implications for autonomy and equity. Addresses genetic discrimination, compulsory treatment based on genetic risk, surveillance expansion, and pathologization of populations through risk identification in healthy individuals. Public health significance—Why is this work of significance to public health? Highlights how genomic technologies influencing resource allocation, insurance, and treatment protocols could exacerbate disparities and undermine informed consent and autonomy. Identifies inadequate protections against genetic discrimination and coercive interventions, potentially creating genetic-based stratification threatening equitable healthcare access. Public health implications—What are the key implications or messages for practitioners, policy makers and/or researchers in public health? Policymakers must develop governance balancing genomic benefits with protections for autonomy, privacy, and equity, including constitutional safeguards and data governance frameworks. Practitioners and researchers should recognize that genomic medicine introduces uncertainty for patients that requires participatory governance, dynamic consent, and reflexive regulation preserving autonomy while enabling beneficial applications. This paper offers a comprehensive analysis of the multifaceted implications of genomic medicine’s evolving regulatory frameworks on individual autonomy. As genomic technologies increasingly permeate healthcare and society, they fundamentally reshape the boundaries of health and disease, profoundly impacting personal identity and self-understanding. The expansion of genomic surveillance and risk classification introduces new forms of scrutiny and vigilance, as individuals are redefined according to probabilistic genetic markers rather than traditional clinical symptoms. Regulatory developments facilitate compulsory interventions and challenge established notions of informed consent, as genetic risk factors in otherwise healthy individuals prompt preemptive medicalization and intervention. These changes heighten the risk of genetic discrimination and reinforce social stratifications, as access to care, insurance, and employment may become contingent upon genomic profiles. Furthermore, the commodification of genetic information raises significant concerns about privacy, ownership, and the potential misuse of personal data by commercial and governmental entities. The increasingly blurred lines between medical necessity and social control highlight constitutional and ethical dilemmas, particularly regarding the balance of public health priorities and the preservation of individual freedoms. Drawing on theoretical frameworks such as Stehr’s knowledge society and governmentality, the paper critically examines how regulatory responses both reflect and shape broader societal values, often introducing persistent uncertainty and vulnerability into the core of personal and collective identity. Ultimately, the analysis underscores the urgent need for innovative governance models that can effectively balance the promise of scientific and technological advances with the protection of personal autonomy, democratic knowledge control, and social justice in the genomic era. Lay statement: This paper explores how new rules and regulations around genetic medicine can impact people’s personal freedoms and sense of identity. It highlights concerns about privacy, discrimination, and the ways in which our understanding of health and disease is changing, calling for better protections and fairer policies as genetic technologies become more common.